ReviewFrontiers in pediatrics2019
Childhood IgA Vasculitis (Henoch Schonlein Purpura)-Advances and Knowledge Gaps.
Review in Frontiers in pediatrics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 99 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
99 citing papers in PubMed, 3 syntheses or guidelines pooled it, 211 citations in OpenAlex.
- Characterization of the neuromuscular manifestations in patients with IgG4-related disease: a systematic review.Immunologic research · 2025Pooled it
- National recommendations for the management of children and young people with IgA vasculitis: a best available evidence, group agreement-based approach.Archives of disease in childhood · 2024Guideline
- A systematic review of urine biomarkers in children with IgA vasculitis nephritis.Pediatric nephrology (Berlin, Germany) · 2021Pooled it
- Infectious triggers in IgA vasculitis in children: current evidence, causal attribution and immunopathogenic mechanisms.Rheumatology international · 2026Review
- Development and validation of a clinical prediction model for gastrointestinal hemorrhage in pediatric IgA vasculitis.BMC pediatrics · 2026Observational
- [More than just purpura-Immunoglobulin A vasculitis in adulthood].Innere Medizin (Heidelberg, Germany) · 2026Article
- The ratio of TG/CysC is a significant indicator of nephritis in children with IgA vasculitis.Journal of clinical biochemistry and nutrition · 2026Article
- Dexmethylphenidate-associated hemorrhagic bullous IgA vasculitis.JAAD case reports · 2026Article
- The Rash That Didn't Blanch: A Case Report of Adult-Onset IgA Vasculitis with Underlying Cirrhosis and IgA Nephropathy.Journal of education & teaching in emergency medicine · 2026Article
- A predictive model based on routine blood inflammatory markers for IgA vasculitis in children.Frontiers in pediatrics · 2026Article
- Emergency in pediatric rheumatology: a narrative review.Frontiers in medicine · 2026Review
- Tfh Cells in Henoch-Schönlein Purpura (IgA Vasculitis): Current Concept.Journal of immunology research · 2026Review
- Advances in multi-omics and therapeutic studies of Henoch-Schönlein purpura.Italian journal of pediatrics · 2025Review
- Article
- Clinical Profile, Renal Involvement, and Relapse Patterns in Pediatric Henoch-Schönlein Purpura: A Retrospective Observational Study from a Tertiary Care Centre in South India.Children (Basel, Switzerland) · 2025Article
- Comprehensive analysis of the clinical and pathological features and prognoses of children with immunoglobulin A vasculitis nephritis with immunoglobulin M deposits in glomeruli.Kidney research and clinical practice · 2025Article
- IgA Vasculitis Across the Ages: Is It Time for a Precision Medicine Approach?ACR open rheumatology · 2025Review
- Evaluation of Serum Complement Components in Pediatric IgA Vasculitis: A Case-Control Study.Children (Basel, Switzerland) · 2025Article
- Henoch-Schönlein Purpura Triggered by Amebiasis in a Young Female Child: A Case Report and Literature Review.Cureus · 2025Article
- Biochemical and structural characterization of the human gut microbiome metallopeptidase IgAse provides insight into its unique specificity for the Fab' region of IgA1 and IgA2.PLoS pathogens · 2025Article
39 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immunoglobulin A vasculitis (IgAV; formerly Henoch Schonlein Purpura) is the most common form of childhood vasculitis. It can occur in any age and peaks around 4-6 years old. It demonstrates seasonal variation implicating a role for environmental triggers and geographical variation. The diagnosis is made clinically and 95% of patients will present with a rash, together with any from a triad of other systems-gastrointestinal, musculoskeletal, and renal. Most cases of IgAV in children have an excellent outcome. Treatment may be required during the acute phase for gastrointestinal involvement and renal involvement, termed IgAV nephritis (previously HSP nephritis), is the most serious long-term manifestation accounting for ~1-2% of all childhood end stage kidney disease (ESKD). It therefore requires a period of renal monitoring conducted for 6-12 months. Patients presenting with nephrotic and/or nephritic syndrome or whom develop significant persistent proteinuria should undergo a renal biopsy to evaluate the extent of renal inflammation and there are now international consensus guidelines that outline the indications for when to do this. At present there is no evidence to support the use of medications at the outset in all patients to prevent subsequent renal inflammation. Consensus management guidelines suggest using oral corticosteroids for milder disease, oral, or intravenous corticosteroids plus azathioprine or mycophenolate mofetil or intravenous cyclophosphamide for moderate disease and intravenous corticosteroids with cyclophosphamide for severe disease. Angiotensin system inhibitors act as adjunctive treatment for persisting proteinuria and frequently relapsing disease may necessitate the use of immunosuppressant agents. Renal outcomes in this disease have remained static over time and progress may be hindered due to many reasons, including the lack of reliable disease biomarkers and an absence of core outcome measures allowing for accurate comparison between studies. This review article summarizes the current evidence supporting the management of this condition highlighting recent findings and areas of unmet need. In order to improve the long term outcomes in this condition international research collaboration is urgently required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.